Gene: ARHGEF6
Official Full Name: Rac/Cdc42 guanine nucleotide exchange factor 6provided by HGNC
Gene Summary: Rho GTPases play a fundamental role in numerous cellular processes that are initiated by extracellular stimuli that work through G protein coupled receptors. The encoded protein belongs to a family of cytoplasmic proteins that activate the Ras-like family of Rho proteins by exchanging bound GDP for GTP. It may form a complex with G proteins and stimulate Rho-dependent signals. This protein is activated by PI3-kinase. Mutations in this gene can cause X-chromosomal non-specific cognitive disability. [provided by RefSeq, Jul 2008]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO33223 | ARHGEF6 Knockout cell line (HCT 116) | Human | ARHGEF6 | 1:2~1:4 | Negative | Online Inquiry |
KO33224 | ARHGEF6 Knockout cell line (HEK293) | Human | ARHGEF6 | 1:3~1:6 | Negative | Online Inquiry |
ARHGEF6 Gene Knockout Cell Lines are genetically modified cell lines designed to facilitate the study of the ARHGEF6 gene's role in various biological processes and disease states. This product involves the targeted deletion of the ARHGEF6 gene, which encodes for a protein acting as a guanine nucleotide exchange factor (GEF) that activates Rho GTPases, crucial players in regulating cellular dynamics, including cytoskeletal organization, cell migration, and proliferation.
The primary mechanism of ARHGEF6 action revolves around its ability to stimulate the exchange of GDP for GTP on Rho proteins, thereby activating signaling pathways involved in cell adhesion and motility. By providing researchers with knockout cell lines, these products offer invaluable tools for dissecting the molecular pathways influenced by ARHGEF6 as well as exploring its implications in pathophysiological contexts, such as cancer metastasis and neurological disorders.
In a research or clinical setting, ARHGEF6 Gene Knockout Cell Lines hold significant importance for elucidating disease mechanisms and validating therapeutic targets. Their capability to model specific genetic alterations allows for rigorous in vitro experimentation to assess the functional consequences of ARHGEF6 loss. Compared to alternative approaches, such as overexpression systems or untargeted gene editing techniques, these knockout lines present a more precise method for understanding gene function while minimizing potential off-target effects.
Researchers, clinicians, and bio-pharma companies can greatly benefit from integrating these cell lines into their workflows, as they provide robust platforms for drug discovery, functional genomics, and the advancement of personalized medicine initiatives. The reliability and specificity of these knockout cell lines bolster their value for scientific inquiries aimed at developing targeted therapies.
With a commitment to innovation and excellence, our company specializes in providing high-quality genetic tools and resources to the scientific community, ensuring researchers have access to reliable and effective models for their investigations.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.